Carbamazepine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Anticonvulsant
Subclass
Iminostilbene derivative
Speciality
Neurology
Schedule (India)
Schedule H
Routes
Oral
Formulations
- Tablets (Immediate-Release): 100 mg, 200 mg, 400 mg
- Controlled-Release (CR) Tablets: 200 mg, 400 mg
- Oral Suspension: 100 mg/5 mL
- Chewable Tablets: 100 mg
Note: Injectable formulation is NOT AVAILABLE in India for routine clinical use
Adult indications
INDICATIONS + DOSING ā FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Partial Seizures (with or without secondary generalisation) and Generalised Tonic-Clonic Seizures
Adults ā Monotherapy or Adjunctive Therapy:
| Parameter | Recommendation |
|---|---|
| Starting dose | 100ā200 mg twice daily |
| Titration | Increase by 200 mg/day every 3ā7 days as tolerated |
| Usual maintenance dose | 800ā1200 mg/day in 2ā3 divided doses |
| Maximum dose | 1600 mg/day |
Clinical Notes:
- Immediate-release formulations require twice or thrice daily dosing
- CR formulations allow twice daily dosing with fewer peak-related adverse effects
- Avoid abrupt withdrawal ā taper gradually over 2ā6 months
- Therapeutic drug monitoring: target trough level 4ā12 mcg/mL
- Not effective for absence seizures ā may worsen them
2. Trigeminal Neuralgia
Adults ā First-line Pharmacotherapy:
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg twice daily |
| Titration | Increase by 100ā200 mg every 2ā3 days based on pain response |
| Usual maintenance dose | 400ā800 mg/day in 2ā3 divided doses |
| Maximum dose | 1200 mg/day |
Clinical Notes:
- Use lowest effective dose to maintain remission
- Periodic dose reduction attempts recommended to assess ongoing requirement
- CR formulations preferred for sustained analgesia
- Response typically seen within first week
3. Bipolar Affective Disorder ā Acute Mania and Maintenance
Adults ā Under Psychiatrist Supervision:
| Parameter | Recommendation |
|---|---|
| Starting dose | 200 mg twice daily |
| Titration | Increase by 200 mg every 3ā5 days based on response and tolerability |
| Usual maintenance dose | 600ā1000 mg/day in divided doses |
| Maximum dose | 1600 mg/day (specialist supervision required) |
Clinical Notes:
- Second-line agent after lithium and valproate in Indian psychiatric practice
- CR formulations preferred to minimise peak-related CNS effects
- Serum level monitoring helpful in non-responders
- Monitor for drug interactions with other psychotropics
Secondary Indications ā Adults Only (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
Diabetic Peripheral Neuropathy ā OFF-LABEL
|
Starting: 100 mg BD; Maintenance: 400ā800 mg/day | 4ā12 weeks trial | Specialist only | Indian pain medicine practice; supportive clinical experience |
|
Restless Leg Syndrome ā OFF-LABEL
|
Starting: 100 mg at bedtime; Max: 400 mg/night | Short-term/intermittent | Specialist only | Limited RCT data; Indian neurology practice |
|
Glossopharyngeal Neuralgia ā OFF-LABEL
|
As per trigeminal neuralgia dosing | As required | Specialist only | Clinical experience; extrapolated from trigeminal neuralgia |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications: Partial Seizures, Generalised Tonic-Clonic Seizures
Age Restriction: Not recommended below 1 month of age except under specialist paediatric neurology supervision.
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose |
|---|---|---|---|---|
| 1ā6 months | 5 mg/kg/day in 2ā3 divided doses | Increase by 5 mg/kg/week | 10ā20 mg/kg/day | 20 mg/kg/day |
| 6 months ā 1 year | 5ā10 mg/kg/day in 2ā3 divided doses | Increase by 5 mg/kg every 5ā7 days | 10ā20 mg/kg/day | 35 mg/kg/day |
| 1ā5 years | 10 mg/kg/day in 2ā3 divided doses | Increase by 5 mg/kg every 5ā7 days | 15ā25 mg/kg/day | 35 mg/kg/day |
| 6ā12 years | 10 mg/kg/day OR 100ā200 mg/day | Increase by 100 mg every 3ā5 days | 20ā30 mg/kg/day OR 400ā800 mg/day | 35 mg/kg/day OR 1000 mg/day |
| >12 years | 100ā200 mg twice daily | Increase by 200 mg every 3ā5 days | 800ā1200 mg/day | 1600 mg/day |
Safety Monitoring:
- Baseline and periodic CBC with differential count
- LFTs at baseline and during first 3 months
- Serum sodium monitoring (risk of SIADH)
- Therapeutic drug monitoring if seizure control inadequate
- CR formulations preferred in older children for better compliance
Secondary Indications ā Paediatric (Off-label)
| Indication | Notes |
|---|---|
|
Trigeminal Neuralgia (rare in children) ā OFF-LABEL
|
Dose as per weight-based seizure guidelines; specialist only |
|
Paediatric Bipolar Disorder ā OFF-LABEL
|
Child psychiatrist supervision mandatory; adolescent dosing applies; monitor for behavioural effects |
Renal Adjustments
| Renal Function | Recommendation |
|---|---|
| Mild impairment (eGFR 60ā89) | No adjustment required |
| Moderate impairment (eGFR 30ā59) | No initial adjustment; monitor for accumulation and adverse effects |
| Severe impairment (eGFR <30) | Use with caution; consider extending dosing interval; monitor drug levels |
| Haemodialysis | Not significantly removed; supplemental dosing generally not required post-dialysis |
| Peritoneal dialysis | No supplemental dosing required |
Hepatic adjustment
Contraindications
- Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic antidepressants
- History of bone marrow depression or blood dyscrasias
- Acute intermittent porphyria
- Concomitant or recent (within 14 days) MAO inhibitor therapy
- Known HLA-B*1502 positivity (high risk of SJS/TEN) ā screening recommended in at-risk populations
- Atrioventricular conduction block (second or third degree)
- Severe hepatic impairment
- Concomitant use with voriconazole (loss of antifungal efficacy)
Cautions
- History of hepatic disease or alcoholism ā enhanced hepatotoxicity risk
- Pre-existing hyponatraemia or conditions predisposing to SIADH
- Cardiac disease, especially arrhythmias or heart failure
- History of haematological reactions to other drugs
- Mixed seizure disorders including absence seizures ā may exacerbate absences
- Elderly patients ā increased sensitivity to CNS effects
- History of psychosis or behavioural disturbance
- Risk of suicidal ideation ā monitor mood and behaviour
- Patients of Asian ancestry (Han Chinese, Thai, Indian populations from certain regions) ā increased HLA-B*1502 prevalence
- Glaucoma ā mild anticholinergic effects
Pregnancy
| Parameter | Details |
|---|---|
| Risk category | Known teratogen; associated with neural tube defects, craniofacial abnormalities, developmental delay |
| Preferred alternatives | Lamotrigine, levetiracetam ā preferred for epilepsy management during pregnancy |
| When may be used | Only if seizure control cannot be achieved with safer alternatives; monotherapy at lowest effective dose preferred |
| Monitoring required | High-dose folic acid (5 mg/day) from preconception through first trimester; targeted anomaly scan at 18ā20 weeks; maternal serum AFP; serial fetal growth monitoring |
| Neonatal concerns | Monitor neonate for withdrawal symptoms and vitamin K deficiency bleeding |
Lactation
| Parameter | Details |
|---|---|
| Compatibility | Generally compatible with breastfeeding; benefits usually outweigh risks |
| Drug levels in milk | Moderate (infant receives approximately 5ā10% of maternal weight-adjusted dose) |
| Preferred alternatives | Lamotrigine, levetiracetam also compatible; valproate carries higher concerns |
| Infant monitoring | Observe for sedation, poor feeding, jaundice, hepatic dysfunction; monitor infant weight gain |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | 100 mg once or twice daily |
| Titration | Very gradual ā increase by 100 mg every 5ā7 days |
| Special risks | Increased CNS depression, ataxia, falls, confusion; hyponatraemia more common; cardiac conduction effects; drug interactions with polypharmacy |
| Monitoring | Serum sodium at baseline and periodically; gait assessment; cognitive monitoring |
Major drug interactions
| Drug/Class | Mechanism/Effect | Recommendation |
|---|---|---|
| MAO inhibitors | Serotonergic crisis risk; unpredictable toxicity |
Contraindicated ā 14-day washout required
|
| Voriconazole | Carbamazepine induces metabolism → subtherapeutic antifungal levels |
Contraindicated ā avoid combination
|
| Clarithromycin, erythromycin | Strong CYP3A4 inhibition → carbamazepine toxicity | Avoid if possible; if unavoidable, reduce carbamazepine dose and monitor levels |
| Valproate | Increases carbamazepine-10,11-epoxide (active/toxic metabolite) | Monitor for toxicity even with "normal" carbamazepine levels |
| Phenytoin, phenobarbital | Mutual enzyme induction → reduced efficacy of both | Monitor levels of both drugs; dose adjustment often needed |
| Warfarin | CYP induction → reduced warfarin effect → decreased INR | Monitor INR closely; warfarin dose increase often required |
| Combined oral contraceptives | Reduced contraceptive efficacy | Advise alternative or additional contraception |
| Doxycycline | Reduced doxycycline half-life and efficacy | Consider alternative antibiotic or higher doxycycline dose |
Moderate drug interactions
| Drug/Class | Effect | Recommendation |
|---|---|---|
| Isoniazid | Inhibits carbamazepine metabolism; additive hepatotoxicity | Monitor LFTs frequently; watch for carbamazepine toxicity |
| Diltiazem, verapamil | Moderate CYP3A4 inhibition → raised carbamazepine levels | Monitor for toxicity; may need dose reduction |
| Fluoxetine, fluvoxamine | CYP inhibition → raised carbamazepine levels | Monitor for CNS toxicity; consider dose adjustment |
| Cimetidine | Inhibits carbamazepine metabolism | Prefer ranitidine or PPIs; monitor if used together |
| Theophylline | Induced metabolism → reduced theophylline levels | Monitor theophylline levels; dose increase may be needed |
| Lithium | Increased risk of neurotoxicity without changing lithium levels | Monitor for tremor, ataxia, confusion; use cautiously |
| Rifampicin | Enzyme induction → reduced carbamazepine efficacy | Monitor seizure control; may need dose increase |
| Methadone | Induced metabolism → reduced methadone effect | Monitor for opioid withdrawal; methadone dose increase may be needed |
Common Adverse effects
- Dizziness and ataxia (especially during initiation and dose increases)
- Nausea and vomiting
- Diplopia and blurred vision
- Drowsiness and fatigue
- Headache
- Dry mouth
- Mild leucopenia (often transient and benign)
- Mild transaminase elevation
- Skin rash (non-serious; discontinue if concerning features)
- Hyponatraemia (SIADH)
Serious Adverse effects
| Adverse Effect | Clinical Action |
|---|---|
| Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis |
Immediate discontinuation and hospitalisation ā especially in HLA-B*1502 positive patients
|
| Aplastic anaemia / Agranulocytosis | Discontinue immediately; urgent haematology referral |
| DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) | Discontinue; supportive care; may require corticosteroids |
| Hepatic failure | Discontinue; liver function monitoring; specialist referral |
| Cardiac arrhythmias / AV block | ECG monitoring; discontinue if significant conduction abnormalities |
| Severe hyponatraemia | May require fluid restriction; discontinuation if severe or symptomatic |
| Suicidal ideation / behavioural changes | Close psychiatric monitoring; consider drug discontinuation |
| Pancreatitis | Discontinue; supportive management |
| Multi-organ hypersensitivity | Immediate discontinuation; hospitalisation |
Monitoring requirements
Baseline:
- Complete blood count with differential
- Liver function tests (AST, ALT, ALP, bilirubin)
- Renal function (serum creatinine, electrolytes)
- Serum sodium
- HLA-B*1502 screening in high-risk populations (North-East India, patients of Han Chinese/Thai ancestry)
- ECG in patients with cardiac history or elderly
- Pregnancy test in women of childbearing age
After Initiation / Dose Change:
- Serum carbamazepine level after steady state achieved (5ā7 days)
- CBC and LFTs at 2 weeks, 4 weeks, then 3 months
- Serum sodium at 2ā4 weeks
- Clinical assessment for rash, CNS effects
Long-term Monitoring:
- CBC and LFTs every 6ā12 months
- Serum sodium every 3ā6 months (more frequently in elderly)
- Annual thyroid function tests
- Bone health assessment with long-term use (vitamin D, calcium, DEXA if indicated)
- Seizure diary review
- Psychiatric assessment for mood and behaviour
Brands in India
Immediate-Release Tablets:
- Tegretol (Novartis)
- Zeptol (Sun Pharma)
- Mazetol (Intas)
- Carbatol (Sanofi)
- Zen (Mankind)
- Carzep (Cipla)
Controlled-Release Tablets:
- Tegretol CR (Novartis)
- Zeptol CR (Sun Pharma)
- Mazetol CR (Intas)
Oral Suspension:
- Tegretol Suspension (Novartis)
- Zeptol Syrup (Sun Pharma)
Chewable Tablets:
- Tegretol Chewable (Novartis)
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablets 100 mg (per tablet) | ā¹1.50āā¹3.00 |
| Tablets 200 mg (per tablet) | ā¹2.00āā¹5.00 |
| Tablets 400 mg (per tablet) | ā¹4.00āā¹8.00 |
| CR Tablets 200 mg (per tablet) | ā¹5.00āā¹8.00 |
| CR Tablets 400 mg (per tablet) | ā¹8.00āā¹12.00 |
| Oral Suspension 100 mL | ā¹40āā¹75 |
- Included in NLEM 2022 for epilepsy
- NPPA price ceiling applicable for scheduled formulations
- Generic options widely available at lower cost
Clinical pearls
- Slow titration is essential ā most CNS and GI adverse effects are dose-related and occur during initiation; gradual uptitration improves tolerability significantly
- HLA-B*1502 testing before initiation ā strongly recommended in patients from North-East India and those of Han Chinese, Thai, or South-East Asian ancestry to identify high-risk individuals for SJS/TEN
- Brand consistency matters ā bioavailability varies between manufacturers; avoid switching brands once seizure control achieved; if switch necessary, monitor closely
- Avoid in absence and myoclonic seizures ā carbamazepine may worsen these seizure types; contraindicated in juvenile myoclonic epilepsy
- Autoinduction phenomenon ā carbamazepine induces its own metabolism over 2ā4 weeks; initial dose may need upward adjustment after this period to maintain therapeutic levels
- Hyponatraemia in elderly ā carbamazepine-induced SIADH is common in patients over 65 years; routine sodium monitoring essential
- Contraceptive counselling mandatory ā enzyme induction significantly reduces efficacy of hormonal contraceptives; advise barrier methods or IUD
Version
RxIndia v1.0 ā 05 Jun 2025
Reference
-
- CDSCO approved product inserts
- Indian Pharmacopoeia
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- AIIMS Treatment Guidelines ā Epilepsy Management
- ICMR Guidelines on Epilepsy
- IAP Paediatric Drug Formulary
- Indian Psychiatric Society treatment protocols
- Indian Epilepsy Society recommendations
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
āļø
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.